Published by Uma Rajagopal
Posted on January 12, 2022
The rise in installation of radiation therapy machines to treat a wide range of cancers further uplifts the probability of radiation toxicity in cancer patients. Future Market Insights (FMI), in its new study on the global radiation toxicity treatment market, foresees that the market will reach the value of US$ 5.5 Bn by the end of forecast period (2019 – 2029) and further experience a major upturn post 2029.
Installed base of internal radiation therapy machines has tremendously increased over the past decade. Improving reimbursement scenario and favorable government policy framework in the field of cancer care are adding to the accessibility of radiation therapy, thereby favoring the growth of radiation toxicity treatment market. The study suggests that notable players in Asia Pacific will continue to invest heavily in the development of new radiation therapies, in line with the increasing cancer prevalence and improving rate of diagnosis in the region.
To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-10724
Key Takeaways – Radiation Toxicity Treatment Market Study
Who Is Winning?
Some of the key players operating in the radiation toxicity treatment market include Amgen Inc., Partner Therapeutics, Mylan N.V., and Novartis AG. Leading players of the radiation toxicity treatment market are focusing on acquiring smaller companies to enhance their product portfolio and improve regional market positioning. For instance, Siegfried Group announced the acquisition of drug product manufacturing facility together with all related employees and contracts from Arena Pharmaceuticals GmbH in Zofingen, Switzerland. Also, in 2018, Partner Therapeutics (PTx) acquired global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.
Get a Customized Scope to Match Your Need, Ask an Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-10724
Know More About the Report
Radiation toxicity treatment market, a new study from future market insights, opines on the evolution of the radiation toxicity treatment market from 2014 – 2018 and presents demand projections from 2019 – 2029 on the basis of; product type (colony stimulating factors, potassium iodide, prussian blue, diethylenetriamine pentaacetic acid, and others), indication (acute radiation syndrome and chronic radiation syndrome), radiation type (ionizing radiation and non-ionizing radiation) and end user (hospitals and research & academic institutes) across seven prominent regions.
Explore Wide-ranging Coverage of FMI’s Market Insights Landscape:
The rise in installation of radiation therapy machines to treat a wide range of cancers further uplifts the probability of radiation toxicity in cancer patients. Future Market Insights (FMI), in its new study on the global radiation toxicity treatment market, foresees that the market will reach the value of US$ 5.5 Bn by the end of forecast period (2019 – 2029) and further experience a major upturn post 2029.
Installed base of internal radiation therapy machines has tremendously increased over the past decade. Improving reimbursement scenario and favorable government policy framework in the field of cancer care are adding to the accessibility of radiation therapy, thereby favoring the growth of radiation toxicity treatment market. The study suggests that notable players in Asia Pacific will continue to invest heavily in the development of new radiation therapies, in line with the increasing cancer prevalence and improving rate of diagnosis in the region.
To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-10724
Key Takeaways – Radiation Toxicity Treatment Market Study
Who Is Winning?
Some of the key players operating in the radiation toxicity treatment market include Amgen Inc., Partner Therapeutics, Mylan N.V., and Novartis AG. Leading players of the radiation toxicity treatment market are focusing on acquiring smaller companies to enhance their product portfolio and improve regional market positioning. For instance, Siegfried Group announced the acquisition of drug product manufacturing facility together with all related employees and contracts from Arena Pharmaceuticals GmbH in Zofingen, Switzerland. Also, in 2018, Partner Therapeutics (PTx) acquired global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.
Get a Customized Scope to Match Your Need, Ask an Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-10724
Know More About the Report
Radiation toxicity treatment market, a new study from future market insights, opines on the evolution of the radiation toxicity treatment market from 2014 – 2018 and presents demand projections from 2019 – 2029 on the basis of; product type (colony stimulating factors, potassium iodide, prussian blue, diethylenetriamine pentaacetic acid, and others), indication (acute radiation syndrome and chronic radiation syndrome), radiation type (ionizing radiation and non-ionizing radiation) and end user (hospitals and research & academic institutes) across seven prominent regions.
Explore Wide-ranging Coverage of FMI’s Market Insights Landscape:
Explore more articles in the Research Reports category
